JAMONY
BCLI

Jacob Asset Management of New York’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Jacob Asset Management of New York’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-367
Closed -$25K – 79
2020
Q4 		$25K Buy
+367
New +$50K 0.02% 68

Other funds holding BCLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jacob Asset Management of New York's BCLI Position: Q1 2021 in Review

Jacob Asset Management of New York sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2021, closing a stake of 367 shares — an estimated $25K sold.

Jacob Asset Management of New York first reported a position in BCLI in Q4 2020 and held it in 1 quarter. The position peaked at $25K in Q4 2020. 75 funds tracked by Wall St. Rank hold BCLI as of Q1 2021.

  • Jacob Asset Management of New York reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2021 after selling out during the quarter.
  • Jacob Asset Management of New York sold 367 BRAINSTORM CELL THERAPUTC shares in Q1 2021, an estimated $25K.
  • Jacob Asset Management of New York first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 1 quarter.
  • Jacob Asset Management of New York's BRAINSTORM CELL THERAPUTC position peaked at $25K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2021.

Based on Jacob Asset Management of New York's 13F filing for Q1 2021, filed 4 Oct 2021.